635.8000 -4.55 (-0.71%)
NSE Sep 03, 2026 11:20 AM
Volume: 93,891
 

635.80
-0.71%
Axis Direct
We expect the whole API industry to continue facing challenges due to a fall in realization as well as an increase in cost pressure. We foresee the situation to continue for the next 2-3 quarters and therefore recommend a HOLD rating on the stock with the target price of Rs 1,300/share.
Solara Active Pharma has gained 23.80% in the last 1 Month
More from Solara Active Pharma Sciences Ltd.
Recommended